Clinical Trial Update: AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating allogeneic human mesenchymal stem cells for frailty, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frailty

Drugs mentioned

• Allogeneic human mesenchymal stem cells (Mesenchymal stem cells)

Snippet

Sponsor: Longeveron Inc. | Conditions: Frailty | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-27